A Pilot Study Comparing the Development of EIAV Env-Specific Antibodies Induced by DNA/Recombinant Vaccinia-Vectored Vaccines and an Attenuated Chinese EIAV Vaccine

Abstract

Data from successful attenuated lentiviral vaccine studies indicate that fully mature Env-specific antibodies characterized by high titer, high avidity, and the predominant recognition of conformational epitopes are associated with protective efficacy. Although vaccination with a DNA prime/recombinant vaccinia-vectored vaccine boost strategy has been found to be effective in some trials with non-human primate/simian/human immunodeficiency virus (SHIV) models, it remains unclear whether this vaccination strategy could elicit mature equine infectious anemia virus (EIAV) Env-specific antibodies, thus protecting vaccinated horses against EIAV infection. Therefore, in this pilot study we vaccinated horses using a strategy based on DNA prime/recombinant Tiantan vaccinia (rTTV)-vectored vaccines encoding EIAV env and gag genes, and observed the development of Env-specific antibodies, neutralizing antibodies, and p26-specific antibodies. Vaccination with DNA induced low titer, low avidity, and the predominant recognition of linear epitopes by Env-specific antibodies, which was enhanced by boosting vaccinations with rTTV vaccines. However, the maturation levels of Env-specific antibodies induced by the DNA/rTTV vaccines were significantly lower than those induced by the attenuated vaccine EIAV_FDDV. Additionally, DNA/rTTV vaccines did not elicit broadly neutralizing antibodies. After challenge with a virulent EIAV strain, all of the vaccinees and control horses died from EIAV disease. These data indicate that the regimen of DNA prime/rTTV vaccine boost did not induce mature Env-specific antibodies, which might have contributed to immune protection failure.

Get full access to this article

View all access options for this article.

References

Brave

, Ljungberg

, Wahren

, Liu

. Vaccine delivery methods using viral vectors. Mol Pharm, 2007; 4:18–32.

Cole

, Rowles

, Jagerski

et al. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J Virol, 1997; 71:5069–5079.

Cook

, Cook

, Bolin

et al. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies. Vet Microbiol, 2005; 108:23–37.

Craigo

, Li

, Steckbeck

et al. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol, 2005; 79:2666–2677.

Craigo

, Zhang

, Barnes

et al. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci USA, 2007; 104:15105–15110.

Donnelly

, Wahren

, Liu

. DNA vaccines: progress and challenges. J Immunol, 2005; 175:633–639.

Fraser

, Leib

, Zhang

, Mealey

, Brown

, McGuire

. Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge. Clin Diagn Lab Immunol, 2005; 12:983–993.

Hammond

, Cook

, Falo

Jr , Issel

, Montelaro

. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology, 1999; 254:37–49.

Hammond

, Cook

, Lichtenstein

, Issel

, Montelaro

. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol, 1997; 71:3840–3852.

10.

Huang

, Lu

, Yu

et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One, 2009; 4:e4180.

11.

Issel

, Coggins

. Equine infectious anemia: current knowledge. J Am Vet Med Assoc, 1979; 174:727–733.

12.

Issel

, Horohov

, Lea

et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol, 1992; 66:3398–3408.

13.

Koup

, Roederer

, Lamoreaux

et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One, 2010; 5:e9015.

14.

, Craigo

, Howe

et al. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol, 2003; 77:7244–7253.

15.

Liang

, He

, Shen

et al. Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV. Arch Virol, 2006; 151:1387–1403.

16.

, Shi

, Jiang

et al. A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity. Virology, 2011; 410:96–106.

17.

Mealey

, Leib

, Littke

, Wagner

, Horohov

, McGuire

. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine, 2009; 27:2453–2468.

18.

Meng

, Li

, Liu

et al. Truncation of cytoplasmic tail of EIAV Env increases the pathogenic necrosis. Virus Res, 2008; 133:201–210.

19.

Meng

, Lin

, Ma

et al. A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies. Arch Virol, 2011; 156:1455–1462.

20.

Raabe

, Issel

, Cook

, Woodson

, Montelaro

. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology, 1998; 245:151–162.

21.

Richmond

, Lu

, Santoro

et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol, 1998; 72:9092–9100.

22.

Richmond

, Mustafa

, Lu

et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology, 1997; 230:265–274.

23.

Sellon

, Fuller

, McGuire

. The immunopathogenesis of equine infectious anemia virus. Virus Res, 1994; 32:111–138.

24.

Shen

, Wang

, Dong

et al. Fetal donkey dermal cells adapted attenuated vaccine of equine infectious anemia virus, its culture methodChinese patent no. 01123620)2001China.

25.

Shen

, Xu

, He

, Zhang

. Study on vaccination of equine infectious anemia. Chin Agricult Sci, 1979; 12:1–15.

26.

Shen

, Liang

, Tong

et al. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine, 2006; 24:738–749.

27.

Singh

, Pandey

, Jayashankar

, Mittal

. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther, 2008; 16:965–971.

28.

Tagmyer

, Craigo

, Cook

, Even

, Issel

, Montelaro

. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol, 2008; 82:4052–4063.

29.

, Ren

, Huang

et al. Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS, 2006; 20:2293–2303.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.09 MB

0.00 MB